Influenza A Infections Market

Market Overview:

The 7 major influenza A infections markets reached a value of USD 5,758.9 Million in ​2024​. Looking forward, IMARC Group expects the 7MM to reach USD 21,812.3 Million by ​2035​, exhibiting a growth rate (CAGR) of 12.87% during ​2025-2035​.

The influenza A infections market has been comprehensively analyzed in IMARC's new report titled "Influenza A Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Influenza A infections are caused by the influenza A virus, a highly contagious pathogen responsible for seasonal flu outbreaks and occasional pandemics. This virus primarily infects the respiratory tract and affects people of all ages. Common symptoms of this condition include a sudden onset of fever, chills, sore throat, cough, muscle pains, exhaustion, and headache. Gastrointestinal signs such as nausea and vomiting may develop, particularly in children. Symptoms usually appear one to four days after exposure and can range from mild to severe, with complications like pneumonia, bronchitis, or aggravation of chronic health conditions in vulnerable populations such as the elderly or immunocompromised people. Diagnosis of influenza A infection is often performed by collecting a respiratory sample (usually from the nose or throat) and testing it for the presence of the flu virus. Rapid influenza diagnostic tests (RIDTs) are widely utilized, however molecular tests such as RT-PCR and other nucleic acid amplification tests (NAATs) are more sensitive and can distinguish between influenza A and B.

The escalating prevalence of viral diseases, in which the virus travels through the air in droplets when someone with the infection coughs, sneezes or talks, is primarily driving the influenza A infections market. In addition to this, the increasing incidence of weakened immunity that can impair the respiratory tract's natural defense mechanisms, making individuals more susceptible to viral infections, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antiviral drugs, like oseltamivir, zanamivir, peramivir, etc., to reduce the severity and duration of flu symptoms among patients is further bolstering the market growth. Apart from this, the rising application of convalescent plasma therapy, since it involves utilizing blood plasma from individuals who have recovered from an infection, containing antibodies that can help fight the same virus, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of live-attenuated influenza vaccine that induces mucosal IgA antibodies, which protect the site of viral entry in the respiratory tract, is expected to drive the influenza A infections market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the influenza A infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of ey companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for influenza A infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the influenza A infections market in any manner.

Recent Developments:

In September 2024, BioCryst Pharmaceuticals, Inc. reported that the United States Department of Health and Human Services (HHS) had granted BioCryst up to a $69 million contract to procure up to 95,625 doses of RAPIVAB (peramivir injectable) for influenza therapy over a five-year period.

In April 2024, Simcere Pharmaceutical and AnDiCon Biotech Co., Ltd. reported that the Phase III clinical study of their anti-influenza novel medicine, Deunoxavir Marboxil Tablets (ADC189), met its primary endpoint with significant efficacy and safety outcomes. Deunoxavir Marboxil tablet is a new treatment for influenza A and B in adults and adolescents, requiring only one oral dose to block influenza virus replication for 24 hours.

Drugs:

Tamiflu (oseltamivir) is a neuraminidase inhibitor used in the prevention and treatment of influenza. Oseltamivir phosphate is a prodrug for the active metabolite (oseltamivir carboxylate), which is a powerful and specific inhibitor of influenza virus neuraminidase enzymes that are glycoproteins located on the virion surface. Viral neuraminidase enzyme activity is critical for viral entry into uninfected cells, the release of newly produced virus particles from infected cells, and the transmission of the infectious virus throughout the body. Oseltamivir action lowers viral shedding and infectivity.

Relenza (Zanamivir) is a neuraminidase inhibitor used to treat influenza A. It particularly targets and inhibits the neuraminidase enzyme, which is required for influenza viruses to detach from infected cells and spread to new cells. Zanamivir efficiently prevents influenza virus replication and spread in the respiratory tract by inhibiting the action of neuraminidase. This restriction in viral transmission reduces flu symptoms and the overall duration of the virus.

Rapivab (peramivir) is an intravenous antiviral medication used to treat acute uncomplicated influenza in individuals aged 2 years and older who have been symptomatic for no more than two days. Peramivir is a neuraminidase inhibitor that functions as a transition-state analogue of influenza neuraminidase, preventing new viruses from arising from infected cells. It is approved for intravenous administration.

Sing2016 M2SR H3N2, developed by FluGen, is an intranasal, live attenuated influenza vaccine engineered with a deletion in the M2 gene, rendering the virus replication deficient. This single-replication design allows the vaccine to mimic natural infection, stimulating robust mucosal, humoral, and cellular immune responses without causing illness. By inducing immunity at the site of viral entry, it offers protection against both matched and drifted influenza A strains.

ADC189 is a cap-dependent nucleic acid endonuclease inhibitor. It works by inhibiting the cap-dependent endonuclease (CEN) of influenza viruses. This enzyme is critical to viral replication and transcription. ADC189 inhibits CEN, preventing the virus from creating new viral RNA and so reducing its capacity to disseminate and replicate.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the influenza A infections market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the influenza A infections market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current influenza A infections marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the influenza A infections market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the influenza A infections market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the influenza A infections market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of influenza A infections across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of influenza A infections by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of influenza A infections by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with influenza A infections across the seven major markets?
• What is the size of the influenza A infections patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of influenza A infections?
• What will be the growth rate of patients across the seven major markets?

Influenza A Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for influenza A infections drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the influenza A infections market?
• What are the key regulatory events related to the influenza A infections market?
• What is the structure of clinical trial landscape by status related to the influenza A infections market?
• What is the structure of clinical trial landscape by phase related to the influenza A infections market?
• What is the structure of clinical trial landscape by route of administration related to the influenza A infections market?